Latest Regulatory Approval News

Duxton Farms has increased its placement to $4.55 million, issuing over 3.6 million new shares to fund the acquisition of four Australian agriculture companies. This move aims to fast-track the company’s diversification and growth strategy in the agricultural investment sector.

3D Energi Limited has updated its prospective gas resource estimates in the Otway Basin, revealing a substantial 9.2 trillion cubic feet (Tcf) of gross recoverable gas across 51 prospects. The company is gearing up for a multi-well drilling campaign in 2025 targeting near-term commercialisation opportunities to bolster East Coast energy security.

Kinterra has increased its takeover offer for New World Resources to A$0.062 per share, positioning its bid as superior and less conditional than rival Central Metals Asia’s scheme proposal. With a significant stake and strategic moves underway, the battle for NWR ownership intensifies.

QPM Energy Limited has launched the Isaac Energy Hub with its first stage, a 112MW gas-fired power station, aiming for mid-2027 commissioning. The company is raising $12 million to support project development and expand its integrated energy utility footprint.

Cambium Bio has secured ethics approvals in Australia and the US to initiate pivotal Phase 3 trials of Elate Ocular, targeting moderate to severe dry eye disease, with patient dosing expected in October 2025.

Actinogen Medical has locked in up to $13.8 million in non-dilutive funding tied to its R&D tax incentives, bolstering its cash position as it advances a pivotal Alzheimer’s disease clinical trial.

Green Critical Minerals’ McIntosh Graphite Project Pre-Feasibility Study confirms robust economics with a post-tax NPV of A$235 million and a 32.5-year mine life, underpinning plans for staged development and market entry.

Actinogen Medical has enrolled its 100th participant in the XanaMIA phase 2b/3 Alzheimer’s trial, setting the stage for a critical interim analysis in January 2026 and final results by year-end.

ECS Botanics has launched the globally acclaimed Terphogz™ cannabis strains, including The Original Z™, into the Australian medicinal market, marking a strategic expansion of its premium product portfolio.

Estrella Resources has confirmed a $5 million capital injection from a strategic investor exercising a tranche subscription option, underpinning its ambitious manganese and limestone projects in Timor-Leste.

Dimerix Limited has received a significant milestone payment from its Japanese partner FUSO Pharmaceutical, marking progress in the Phase 3 clinical trial of DMX-200 for kidney disease. This payment underscores the growing momentum behind Dimerix’s global licensing strategy.

Brightstar Resources has completed a Definitive Feasibility Study for its Menzies and Laverton Gold Projects, outlining a robust staged development plan with strong financial returns and a targeted final investment decision in 2025.